X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs IPCA LABS - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA IPCA LABS AUROBINDO PHARMA/
IPCA LABS
 
P/E (TTM) x 21.4 28.1 76.3% View Chart
P/BV x 4.0 3.6 112.4% View Chart
Dividend Yield % 0.3 0.1 237.3%  

Financials

 AUROBINDO PHARMA   IPCA LABS
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
IPCA LABS
Mar-18
AUROBINDO PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs809695 116.3%   
Low Rs504400 126.0%   
Sales per share (Unadj.) Rs281.1260.2 108.0%  
Earnings per share (Unadj.) Rs41.419.0 218.0%  
Cash flow per share (Unadj.) Rs50.933.1 153.9%  
Dividends per share (Unadj.) Rs2.501.00 250.0%  
Dividend yield (eoy) %0.40.2 208.6%  
Book value per share (Unadj.) Rs199.4213.0 93.6%  
Shares outstanding (eoy) m585.88126.20 464.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.32.1 111.0%   
Avg P/E ratio x15.928.9 55.0%  
P/CF ratio (eoy) x12.916.6 77.9%  
Price / Book Value ratio x3.32.6 128.1%  
Dividend payout %6.05.3 114.7%   
Avg Mkt Cap Rs m384,63069,120 556.5%   
No. of employees `00017.313.3 130.8%   
Total wages/salary Rs m21,3087,359 289.6%   
Avg. sales/employee Rs Th9,500.72,477.4 383.5%   
Avg. wages/employee Rs Th1,229.4555.2 221.4%   
Avg. net profit/employee Rs Th1,397.9180.6 773.9%   
INCOME DATA
Net Sales Rs m164,66632,836 501.5%  
Other income Rs m1,020418 244.0%   
Total revenues Rs m165,68633,254 498.2%   
Gross profit Rs m37,7184,505 837.3%  
Depreciation Rs m5,5801,777 313.9%   
Interest Rs m777240 323.6%   
Profit before tax Rs m32,3802,905 1,114.5%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,183511 1,601.0%   
Profit after tax Rs m24,2292,394 1,012.0%  
Gross profit margin %22.913.7 167.0%  
Effective tax rate %25.317.6 143.6%   
Net profit margin %14.77.3 201.8%  
BALANCE SHEET DATA
Current assets Rs m121,87819,455 626.5%   
Current liabilities Rs m86,80610,076 861.5%   
Net working cap to sales %21.328.6 74.6%  
Current ratio x1.41.9 72.7%  
Inventory Days Days13098 132.7%  
Debtors Days Days6867 102.1%  
Net fixed assets Rs m81,03720,260 400.0%   
Share capital Rs m586252 232.1%   
"Free" reserves Rs m116,21826,633 436.4%   
Net worth Rs m116,80426,886 434.4%   
Long term debt Rs m4,5122,340 192.8%   
Total assets Rs m211,05241,173 512.6%  
Interest coverage x42.713.1 325.8%   
Debt to equity ratio x00.1 44.4%  
Sales to assets ratio x0.80.8 97.8%   
Return on assets %11.86.4 185.2%  
Return on equity %20.78.9 232.9%  
Return on capital %27.410.8 254.2%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m80,72715,642 516.1%   
Fx outflow Rs m34,7004,884 710.5%   
Net fx Rs m46,02710,759 427.8%   
CASH FLOW
From Operations Rs m19,5483,411 573.0%  
From Investments Rs m-19,570-1,354 1,445.3%  
From Financial Activity Rs m8,642-1,304 -662.6%  
Net Cashflow Rs m8,922753 1,184.6%  

Share Holding

Indian Promoters % 54.1 45.9 117.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 11.4 69.7%  
FIIs % 27.7 25.3 109.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 17.4 58.6%  
Shareholders   69,601 36,892 188.7%  
Pledged promoter(s) holding % 8.6 2.1 400.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ALKEM LABORATORIES  PLETHICO PHARMA  GLENMARK PHARMA  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 274 Points Lower; IT and Energy Stocks Witness Selling(Closing)

Share markets in India continued to witness selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Nov 21, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS